Professional
Added to YB: 2026-04-14
Pitch date: 2026-04-10
VIR [bullish]
Vir Biotechnology, Inc.
+4.77%
current return
Author Info
No bio for this author
Company Info
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally.
Market Cap
$1.6B
Pitch Price
$9.12
Price Target
N/A
Dividend
N/A
EV/EBITDA
-2.75
P/E
-2.97
EV/Sales
18.21
Sector
Biotechnology
Category
growth
Jacob Small Cap Growth Fund New Position: Vir Biotechnology, Inc.
VIR (new position): Immunotherapy leader in Bispecific T-Cell engagers (BiTEs) for oncology & infectious disease (hep delta, HIV). Proprietary Sanofi-licensed masking tech activates only at diseased cells, boosting efficacy while cutting off-target toxicity vs peers. Astellas collab post-Phase 1 prostate data funds trials for next several years.
Read full article (1 min)